Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880268 | 0.83 | LMNA (0.61) | LMNASMN1; SMN2TP53KMT2AALDH1A1 | |
| SCHEMBL18268208 | 0.78 | KDM4E (0.41) | SMN1; SMN2TP53KMT2AALDH1A1MAPK1 | |
| SCHEMBL18268192 | 0.77 | LMNA (0.69) | LMNASMN1; SMN2TP53KMT2AALDH1A1 | |
| SCHEMBL880238 | 0.76 | ALDH1A1 (0.51) | LMNASMN1; SMN2TP53KMT2AALDH1A1 | |
| SCHEMBL18268197 | 0.74 | LMNA (0.59) | LMNASMN1; SMN2TP53KMT2AALDH1A1 | |
| SCHEMBL15077972 | 0.74 | NPC1 (0.43) | LMNASMN1; SMN2TP53KMT2AALDH1A1 | |
| SCHEMBL18268204 | 0.70 | LMNA (0.47) | LMNASMN1; SMN2TP53KMT2AALDH1A1 | |
| SCHEMBL18268193 | 0.69 | CA2 (0.39) | LMNAKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL25492207 | 0.68 | LMNA (0.52) | LMNASMN1; SMN2TP53KMT2AALDH1A1 | |
| SCHEMBL22126270 | 0.67 | TP53 (1.00) | LMNASMN1; SMN2TP53ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987294-B2 | Small molecule inhibitors of the α4-paxillin interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987294-B2 | Small molecule inhibitors of the α4-paxillin interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120245194-A1 | SMALL MOLECULE INHIBITORS OF THE ALPHA4-PAXILLIN INTERACTION | University of California Technology Transfer (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245194-A1 | SMALL MOLECULE INHIBITORS OF THE ALPHA4-PAXILLIN INTERACTION | University of California Technology Transfer (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011034896-A2 | SMALL MOLECULE INHIBITORS OF THE ALPHA4-PAXILLIN INTERACTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245194-A1 | SMALL MOLECULE INHIBITORS OF THE ALPHA4-PAXILLIN INTERACTION | ILK, LPXN, DOCK5 | LMNA 460/4885SMN1; SMN2 2208/4885TP53 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.